千金药业：子公司获得药品注册证书

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received the drug registration certificate for Lurasidone Hydrochloride Tablets from the National Medical Products Administration, marking a significant milestone for the company in the psychiatric medication market [1] Group 1: Drug Approval and Market Context - The drug Lurasidone Hydrochloride Tablets is indicated for the treatment of schizophrenia and was originally developed by Sunovion Pharmaceuticals Inc., first launched in the U.S. in October 2010 and approved for import in China in January 2019 [1] - Other companies that have obtained registration for Lurasidone Hydrochloride Tablets in China include Jiangsu Hengrui Medicine Co., Ltd., Chengdu Kanghong Pharmaceutical Group Co., Ltd., and Zhejiang Hisun Pharmaceutical Co., Ltd. [1] - According to data from MoSheng Pharmaceuticals, the domestic market sales for Lurasidone Hydrochloride Tablets are projected to be approximately 52 million yuan in the first half of 2025 [1] Group 2: R&D Investment - As of the date of the announcement, Qianjin Xiangjiang Pharmaceutical has invested a total of 6.3294 million yuan in the research and development of Lurasidone Hydrochloride Tablets [1]